SC rejects Bayer's appeal against compulsory licence for Nexavar
Indian pharma company, NATCO, can continue manufacturing generic version of liver and kidney cancer drug
Activists demand compulsory licence for another life-saving cancer drug
Appellate board's order upholding Natco's CL for sorafenib tosylate may pave way for manufacture of generic version of other patented drugs
Will appellate body uphold grant of compulsory licence to cancer drug?
Hearing on Bayer's appeal against manufacture of generic version of Nexavar to conclude this week
Indian company gets licence to manufacture and sell patented cancer drug
This is the first-ever compulsory licence given to a generic drug company